Публикации

2022 год

• Сантос Г.М., Икеда Дж., Коффин П., Уокер Дж., Мэтисон Т., Али А., Маклафлин М., Джайн Дж., Аренандер Дж., Виттингхофф Е., Батки С. Налтрексон для перорального применения при легкой и умеренной степени расстройства, связанного с употреблением алкоголя, среди мужчин из числа сексуальных и гендерных меньшинств: Рандомизированное исследование. Американский журнал психиатрии. 26 октября 2022 г. doi:10.1176/appi.ajp.20220335. Epub онлайн перед печатью. PMID: 36285404

• Маклафлин М.Ф., Джайн Дж.П., Икеда Дж., Уокер Дж.Э., Коффин П., Сантос ГМ. Корреляты высоких уровней фосфатидилэтанола (Peth) и их соответствие с самооценками злоупотребления алкоголем среди мужчин, занимающихся сексом с мужчинами, злоупотребляющими алкоголем. Алкоголизм, клинические и экспериментальные исследования. Алкогольная клиника Exp Res. 20 июня 2022 г. doi: 10.1111/acer.14891. Epub онлайн перед печатью. PMID: 35722862

​

2021

• Дэви-Мендес Т., Виттингхофф Э., Дилворт С.Э., Суэн Л.В., Браун С., Коффин П.О., Сатре Д.Д., Райли ЭД. Несмертельная передозировка стимуляторами среди бездомных и женщин с нестабильным жильем в Сан-Франциско, Калифорния. Зависимость от алкоголя и наркотиков. 2021, 22 сентября;228:109085. doi: 10.1016/j.drugalcdep.2021.109085. Epub перед печатью. PMID: 34600248.

2018 год

• Смит-Бернардин С., Роу С., Бехар Э., Гейер М., Вашингтон С., Сантос Г.М., Юрен Дж., Мартин Дж., Глегхорн А., Коффин П.О. Низкопороговое налтрексон пролонгированного действия для часто пользующихся общественными услугами людей с тяжелым расстройством, вызванным употреблением алкоголя: пилотное исследование. J Лекарство от злоупотребления наркотиками. 2018 февраль;85:109-115. doi: 10.1016/j.jsat.2017.11.005. Epub, 8 ноября 2017 г. PMID: 29150316.

2023 год

• Суэн Л.В., Виттингхофф Э., Ву АХБ, Рави А., Коффин П.О., Сюэ П., Линч К.Л., Кази Д.С., Райли ЭД. Многократное употребление психоактивных веществ и артериальное давление у бездомных женщин. Отчеты о аддиктивном поведении. 2023, 13 февраля; 17: 100483. doi:10.1016/j.abrep.2023.100483. Epub перед печатью. PMID: 36875801.

2022 год

• Райли ЭД, Кази Д.С., Коффин П.О., Виттингхофф Э., Уэйд А.Н., Бульфоне Т.К., Линч К.Л., Атай З., Ву АХБ. Влияние употребления нескольких психоактивных веществ на циркулирующий ST2, биомаркер неблагоприятного ремоделирования сердца, у женщин. Биомаркеры. 2022 декабря;27(8):802-808. дои: 10.1080/1354750X.2022.2129451. Epub перед печатью. PMID: 36168954

2021 год

• Дэви-Мендес Т., Виттингхофф Э., Дилворт С.Э., Суэн Л.В., Браун С., Коффин П.О., Сатре Д.Д., Райли ЭД. Несмертельная передозировка стимуляторами среди бездомных и женщин с нестабильным жильем в Сан-Франциско, Калифорния. Зависимость от алкоголя и наркотиков. 2021, 22 сентября;228:109085. doi: 10.1016/j.drugalcdep.2021.109085. Epub перед печатью. PMID: 34600248.

• Сантос Г.М., Икеда Дж., Коффин П., Уокер Дж.Э., Мэтисон Т., Маклафлин М. и др. (2021) Пилотное исследование лоркасерина пролонгированного действия при расстройстве, связанном с употреблением кокаина, среди мужчин, занимающихся сексом с мужчинами: двойное слепое плацебо-контролируемое рандомизированное исследование. ПЛОС ОДИН. 15 июля 2021 г.; 16 (7): e0254724. doi: 10.1371/journal.pone.0254724. PMID: 34265007.

2026​​

• Black FRN, Santos GM, McMahan VM, Fraser AB, Clark J, Sturgeon L, Walker JF, Kochanska M, Shoptaw S, Coffin PO. Safety of intravenous methamphetamine in patients taking mirtazapine: a two-site phase 1b randomized controlled trial. J Clin Psychopharmacol. Published online March 4, 2026. doi:10.1097/JCP.0000000000002148. 

​

• Appa A, Steiner G, Baral S, Riley E, Suchman L, Roberts K, Knight K, Murphy M, Chamie G, Shoptaw S, Coffin PO, Gandhi M. Integrating HIV and stimulant use disorder treatment: a pilot implementation effectiveness trial of contingency management in HIV care. Clin Infect Dis. Published online January 8, 2026. doi:10.1093/cid/ciag006.

​

2025​​

• Appa A, Marti XL, Baral S, Shoptaw S, Bazazi AR, Spinelli MA, Glidden D, Gandhi M, Coffin P.Addict Sci Clin Pract. 2025 Dec 15. doi: 10.1186/s13722-025-00623-5. Online ahead of print.PMID: 41398703 The NOD (Naltrexone for Overdose Prevention) study protocol: a pilot randomized controlled trial of intramuscular naltrexone for opioid overdose prevention among people who use stimulants living with or at risk for HIV. 

​

• Jha MK, Ghitza UE, Shoptaw S, Minhajuddin A, Kuruvila S, Wakhlu S, Nunes EV, Schmitz J, Coffin PO, Bart G, Carmody T, Trivedi MH. Early Change in Depressive Symptom Severity With Naltrexone-Bupropion Combination and Its Association With Reduction in Methamphetamine Use in ADAPT-2 Trial. Journal of Clinical Psychiatry. 2025 Jul 30;86(3):25m15825. doi: 10.4088/JCP.25m15825. PMID: 40767786.

​

• Jha MK, Ghitza UE, Carmody T, Kuruvila S, Shoptaw S, Minhajuddin A, Wakhlu S, Schmitz JM, Coffin PO, Bart G, Nunes EV, Kenny P, Trivedi MH. Craving, Impulsivity, and Subsequent Methamphetamine Use With Naltrexone-Bupropion Versus Placebo: Findings From a Randomized Clinical Trial. Journal of Addiction Medicine. 2025 Jul 7. doi: 10.1097/ADM.0000000000001538. Online ahead of print. PMID: 40623319.

​

• Rush CR, Santos GM, McMahan VM, Fraser A, Clark J,  Luna Marti X, Walker JE, Shoptaw S, Coffin PO. Mirtazapine reduces hypothetical methamphetamine demand in humans. Drug and Alcohol Dependence. 2025 Sep 10. https://doi.org/10.1016/j.drugalcdep.2025.112769. Epub 2025 June 27.

​

• McMahan VM, Pope E, Luna Marti X, Walker J, Liu AY, Coffin PO. Interest in Long-Acting Preexposure Prophylaxis (PrEP) Among Men at Risk for Human Immunodeficiency Virus Who Use Methamphetamine Participating in a Daily, Oral PrEP Adherence Trial in San Francisco, California. Open Forum Infectious Diseases. 2025 May 12. https://doi.org/10.1093/ofid/ofaf280.

​

2024

• Coffin PO, Chang Y, McDaniel M, Leary M, Pating D, McMahan VM, Goldman ML. Evaluation of methamphetamine assist packs: As-needed antipsychotics for self-management of methamphetamine-associated psychiatric toxicity. International Journal of Drug Dependency. 2024 June 10. https://doi.org/10.1016/j.drugpo.2024.104480. Epub 2024 June 10.

​

2023

• Kidd JD, Smiley SL, Coffin PO, Carmody TJ, Levin FR, Nunes EV, Shoptaw SJ, Trivedi MH. Sexual orientation differences among men in a randomized clinical trial of extended-release naltrexone and bupropion for methamphetamine use disorder. Drug Alcohol Depend. 2023 Sep 1;250:110899. doi: 10.1016/j.drugalcdep.2023.110899. Epub 2023 Jul 17. PMID: 37478502.

2022

• Riley ED, Hsue PY, Coffin PO. A chronic condition disguised as an acute event: The case for re-thinking stimulant overdose death. J Gen Intern Med. 2022 Jun 17. doi: 10.1007/s11606-022-07692-1. Online ahead of print. PMID: 35713806.

​

2021

• Trivedi MH, Walker R, Ling W, Cruz A, Sharma G, Carmody T, Ghitza UE, Wahle A, Kim M, Shores-Wilson K, Sparenborg S, Coffin P, Schmitz J, Wiest K, Bart G, Sonne S, Wakhlu S, Rush, AJ, Nunes EV, Shoptaw S. Trial of bupropion and naltrexone in methamphetamine use disorder. New England Journal of Medicine. 2021 Jan 14;384;2. 140-153. doi: 10.1056/NEJMoa2020214. PMID: 33497547.

​

2020

• Coffin PO, Santos G-M, Hern J, Vittinghoff E, Walker JE, Matheson T, Santos D, Colfax G, Batki SL. Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial. JAMA Psychiatry. 2020 Mar 1;77(3):246-255. Doi: 10.1001/jamapsychiatry.2019.3655. PMID: 31825466. 

​

2018

• Rowe C, Vittinghoff E, Colfax G, Coffin PO, Santos GM. Correlates of Validity of Self-Reported Methamphetamine Use among a Sample of Dependent Adults. Substance Use & Misuse. 2018 Aug 24;53(10):1742-1755. doi: 10.1080/10826084.2018.1432649.  

​

• Coffin PO, Santos GM, Hern J, Vittinghoff E, Santos D, Matheson T, Colfax G, Batki SL. Extended-release naltrexone for methamphetamine dependence among men who have sex with men: a randomized placebo-controlled trial. Addiction. 2018 Feb;113(2):268-278. doi: 10.1111/add.13950. PMID: 28734107.

​

2016

• Santos GM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Hahn JA, Vlahov D, Vittinghoff E, Batki SL. Feasibility, acceptability and tolerability of targeted naltrexone for non-dependent methamphetamine-using and binge-drinking men who have sex with men. Journal of Acquired Immunodeficiency Syndromes. 2016; 72(1):21-30. Doi: 10.1097/AAI. 0000000000000922 PMID: 26674372.​​

​

2014

• Hermanstyne K, Santos GM, Colfax G, Vittinghoff E, Coffin PO. Event-level relationship between methamphetamine use significantly associated with non-adherence to pharmacologic trial medications in event-level analyses. Drug and Alcohol Dependence. 2014 Aug 5. pii: S0376-8716(14)01020-5. http://dx.doi.org/doi:10.1016/j.drugalcdep.2014.07.031.PMID: 25156227.​​

​

2010-2013

• Coffin PO, Santos GM, Das M, Santos D, Huffaker S, Matheson T, Gasper J, Vittinghoff E, Colfax G. Aripiprazole for the treatment of methamphetamine dependence: a randomized, double-blind, placebo-controlled trial. Addiction. 2013 Apr;108(4):751-61. PMID 23186131.

​

• Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, Shoptaw S, Vittinghoff E. Mirtazapine to reduce methamphetamine use: a randomized controlled trial. Arch Gen Psychiatry. 2011 Nov; 68(11):1168-75. PMID: 22065532. 

​

• Colfax G, Santos GM, Chu P, Vittinghoff E, Pluddemann A, Kumar S, Hart C. Amphetamine-group substances and HIV. Lancet. 2010 Aug 07; 376(9739):458-74. PMID: 20650520.

2026​

• Suen LW, Chang YG, McMahan VM, Beliveau CM, Arenander J, Chiang A, Coffin PO. Stimulant Use After Loss of Access to Prescribed Opioids for Chronic Noncancer Pain.  Am J Prev Med. 2026 May 28;71(4):108437. doi: 10.1016/j.amepre.2026.108437. Online ahead of print. PMID: 42314278

​

• Anderson N, McMahan VM, Tomashevsky I, Hom JK, Coffin PO. The contribution of homelessness to opioid overdose mortality and associated racial disparities. J Urban Health. Published online 2026. doi:10.1007/s11524-026-01084-0. 

​

• Chang Y-SG, McMahan VM, Rodda LN, Antolin Muñiz M, Brennan S, Luna Marti X, Lutz SM, Knoll J, Coffin PO. Antecedents of fentanyl coinvolvement in deaths attributed to stimulant poisoning in San Francisco, CA. J Addict Med. Published online February 10, 2026. doi:10.1097/ADM.0000000000001661.

​

• Suen LW, Samayoa E, Spinelli MA, Scarpetta M, Knight KR, Chael J, Soran CS, Geier M, Snyder HR, Coffin PO. “It’s like scratching at the door”: Experiences of outpatient buprenorphine low-dose initiation among people using fentanyl. J Subst Use Addict Treat. 2026;184:209893. doi:10.1016/j.josat.2026.209893. 

​

• McCann N, Yan S, McMahan VM, Rich ZC, Pope E, Rolles A, Brennan S, Luna Marti X, Kosakowski S, Matheson T, Coffin PO, Walley AY. Witnessed overdose history and response among overdose survivors who use non-prescribed opioids in an overdose prevention trial. Addict Behav. 2026;173:108558. doi:10.1016/j.addbeh.2025.108558.

​

• Parizher, J., Panigrahi, A., Geier, M., Soran, C. S., Snyder, H. R., Knight, K., Coffin, P. O., & Suen, L. W. (2026). Qualitative study of bubble pack use during buprenorphine low dose initiation. Journal of the American Pharmacists Association : JAPhA, 103130. Advance online publication. https://doi.org/10.1016/j.japh.2026.103130

​

2025​

• Bagley SM, Maschke AD, Harris MTH, Walley AY, Johnson S, Hurstak E, et al. A qualitative study exploring motivations for participating in research among women who use opioids. PLoS One. 2025;20(11):e0336061. doi:10.1371/journal.pone.0336061. 

​

• Coffin PO, Santos GM, McMahan VM, Luna Marti X, et al. Repeated-dose behavioral intervention to reduce opioid overdose among overdose survivors with opioid use disorder: a two-site phase III randomized controlled trial. Addiction. 2026;121(3):643-654. doi:10.1111/add.70252

​

• Chang Y-S G, Anderson N, Long K, Murphy C, McMahan VM, Rodda LN, Kral AH, Coffin PO. Refining cause of death attribution among opioid, opioid-stimulant and stimulant acute toxicity deaths. Addiction. 2026;121(2):288-294. doi:10.1111/add.70190. 

​

• Chang YG, McMahan VM, Matheson T, Luna Marti X, Robinson M, Rolles A, Kosakowski S, Santos GM, Walley AY, Coffin PO. The Association of Perceived Risk for Opioid Overdose and Subsequent Overdose Among a Cohort of Opioid Overdose Survivors Who Use Nonprescribed Opioids. Substance Use and Addiction Journal. 2025 Jul 23:29767342251355116. doi: 10.1177/29767342251355116. Online ahead of print. PMID: 40698403.

​

• Otero M, Shih J, Zhou B, Eng M, Ghandi S, Talbott J, Singhal NS, Calabrese E, Randazzo D, Coffin PO, Hemphill JC, Amorim E. Neurological Injury and Outcomes in Fentanyl-related Cardiac Arrest. Journal of Addiction Medicine. 2025 Jul 8. DOI: 10.1097/ADM.0000000000001554.

• Smith RJ, McMahan VM, McCann NC, Kosakowski S, Brennan S, Marti XL, Walley AY, Coffin PO. Emergency medical system response, emergency department visits, and hospital admissions in response to non-fatal opioid overdoses reported by a cohort of overdose survivors in San Francisco and Boston, 2019 - 2022. Drug and Alcohol Dependence Reports. 2025 Jun 10;16:100351. doi: 10.1016/j.dadr.2025.100351. eCollection 2025 Sep. PMID: 40606798.

​

• Coffin PO. Everything in moderation, even naloxone. Addiction. 2025 May 21. https://doi.org/10.1111/add.70096.

​

• ​Long KL, McMahan VM, Shade S, Liu I, Santos G-M, Coffin PO. Receipt of prescribed opioids is associated with achieving quality healthcare indicators among patients with chronic non-cancer pain. Journal of Public Health. 2025 May 16. doi.org: 10.1007/s10389-025-02495-0.

​

• McCann NC, Yan S, McMahan VM, Pope E, Rolles A, Brennan S, Marti XL, Kosakowski S, Coffin PO, Walley AY. Test-Retest Reliability of a Timeline Follow-back Method to Assess Opioid Use and Treatment. Journal of Addiction Medicine. 2025 Feb 5. doi: 10.1097/ADM.0000000000001451. Online ahead of print. PMID: 39908533.

​

2024

• BLH, Geier M, Neuhaus J, Coffin PO, Snyder HR, Soran CS, Knight KR, Suen LW. Withdrawal during outpatient low dose buprenorphine initiation in people who use fentanyl: a retrospective cohort study. Harm Reduct J. 2024 Apr 9;21(1):80. doi: 10.1186/s12954-024-00998-9. PMID: 38594721.

​

2022

• Coffin PO, Martinez RS, Wylie B, Ryder B. Primary care management of Long-Term opioid therapy​. Ann Med. 2022 Dec;54(1):2451-2469. doi: 10.1080/07853890.2022.2121417. PMID: 36111417. 

​

• Coffin PO, McMahan VM, Murphy C. Evidence of Pre-mortem Opioid Use among Fentanyl Overdose Decedents in a Safety Net Healthcare System. J Urban Health. 2022 Oct;99(5):865-872. doi: 10.1007/s11524-022-00663-1. PMID: 35879486.

​

• LeSaint LT, Montoy JCC, Silverman EC, Raven MC, Schow SL, Coffin PO, Brown JF, Mercer MP. Implementation of a Leave-behind Naloxone Program in San Francisco: A One-year Experience. West J Emerg Med. 2022 Oct 31;23(6):952-957. doi: 10.5811/westjem.2022.8.56561. PMID: 36409939.

​

• Silvis J;Rowe CL;Dobbins S;Haq N;Vittinghoff E;McMahan VM;Appa A;Coffin PO; Engagement in HIV care and viral suppression following changes in long-term opioid therapy for treatment for chronic pain. AIDS and Behavior. 2022 Oct;26(10):3220-3230. doi: 10.1007/s10461-022-03671-z. PMID: 35380287.

​

• McMahan VM, Arenander J, Matheson T, Lambert AM, Brennan S, Green TC, Walley AY, Coffin PO. "There's No Heroin Around Anymore. It's All Fentanyl." Adaptation of an Opioid Overdose Prevention Counseling Approach to Address Fentanyl Overdose: Formative Study. JMIR Form Res. 2022 Sep 7;6(9):e37483. doi: 10.2196/37483. PMID: 36069781.

​

• Coffin PO, Maya S, Kahn JG. Modeling of overdose and naloxone distribution in the setting of fentanyl compared to heroin. Drug and Alcohol Dependence. 2022 Jul 1;236:109478. doi:10.1016/j.drugalcdep.2022.109478. PMID: 35588609.

​

• Tierney HR, Rowe CL, Coffa DA, Sarnaik S, Coffin PO, Snyder HR. Methadone treatment and patient-directed hospital discharges among patients with opioid use disorder: Observations from general medicine services at an urban, safety-net hospital. Drug Alcohol Depend Rep. 2022 May 14;3:100066. doi: 10.1016/j.dadr.2022.100066. PMID: 36845982.

​

2021

• Rowe CL, Eagen K, Ahern J, Faul M, Hubbard A, Coffin P. Evaluating the Effects of Opioid Prescribing Policies on Patient Outcomes in a Safety-net Primary Care Clinic. J Gen Intern Med. 2021 Jun 25;doi: 10.1007/s11606-021-06920-4. Epub ahead of print. PMID: 34173204.

​

• Rowe CL, Ahern J, Hubbard A, Coffin PO. Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program. J Subst Abuse Treat. 2021 Apr 30;132:108452. doi: 10.1016/j.jsat.2021.108452. Online ahead of print. PMID: 34098203

​

• Tierney HR, Rowe CL, Coffa DA, Sarnaik S, Coffin PO, Snyder HR. Inpatient Opioid Use Disorder Treatment by Generalists is Associated With Linkage to Opioid Treatment Programs After Discharge. J Addict Med. 2021 Apr 2. doi: 10.1097/ADM.0000000000000851. PMID: 33813579.

​

• Haq N, McMahan VM, Torres A, Santos GM, Knight K, Kushel M, Coffin PO. Race, pain, and opioids among patients with chronic pain in a safety-net health system. Drug Alcohol Depend. 2021 Mar 18:108671. doi: 10.1016/j.drugalcdep.2021.108671. PMID: 33810908.

​

• The OUD Modeling Writing Group [Coffin PO]. How simulation modeling can support the public health response to the opioid crisis in North America: Setting priorities and assessing value. Int J Drug Policy. 2021 Feb;88:102726. doi: 10.1016/j.drugpo.2020.102726. PMID: 32359858.

​

2020

• Coffin PO, Rowe C, Oman N, Sinchek K, Santos G-M, Faul M, Bagnulo R, Mohamed D, Vittinghoff E. Illicit Opioid Use following Changes in Opioids Prescribed for Chronic Non-Malignant Pain. PLOS ONE. 2020 May 4;15(5):e0232538. doi: 10.1371/journal.pone.0232538. eCollection 2020. PMID: 32365132.

​

• Behar E, Bagnulo R, Knight K, Santos GM, Coffin PO. "Chasing the pain relief, not the high”: Experiences managing pain after opioid reductions among patients with HIV and a history of substance use. PLOS ONE. 2020 Mar 25;15(3): e0230408. https://doi.org/10.1371/journal.pone.0230408

​

• Meacham MC, Lynch KL, Coffin PO, Wade A, Wheeler E, Riley ED. Addressing overdose risk among unstably housed women in San Francisco, California: An examination of potential fentanyl contamination of multiple substances. Harm Reduction Journal. 2020 Mar 10; 17(1):17. Doi 10.1186/s12954-020-00361-8. PMID: 32156289. 

​

2019

• Chang JS, Behar E, Coffin PO. Narratives of people who inject drugs on factors contributing to opioid overdose. Int J Drug Policy. 2019 Dec;74:26-32. doi: 10.1016/j.drugpo.2019.07.038. PMID: 31442677.

​

• Rowe C, Riley E, Eagen K, Zevin B, Coffin PO. Drug overdose mortality among residents of single room occupancy buildings in San Francisco, California, 2010-2017. Drug and Alcohol Dependence. 2019 Nov 1;204:107571. doi: 10.1016/j.drugalcdep.2019.107571. PMID: 31581024. 

​

• Wenger LD, Showalter D, Lambdin B, Leiva D, Wheeler E, Davidson PJ, Coffin PO, Binswanger IA, Kral AH. Overdose education and naloxone distribution in the San Francisco County jail. Journal of Correctional Health Care. 2019 Oct 31;25(4):394-404. doi: 10.1177/1078345819882771. PMID: 31672075 

​

• Behar E, Chang J, Countess K, Matheson T, Santos G-M, Coffin PO. Perceived causes of personal versus witnessed overdoses among people who inject opioids. Substance Use and Misuse. 2019 May 9:1-9. doi: 10.1080/10826084.2019.1609988. PMID: 31070106.

​

• Coffin PO, Rich JD. Overdose research: 15 years later. Journal of Urban Health. 2019. Jan 8. https://doi.org/10.1007/s11524-018-00344-y. PMID: 30180774.​​​

​

2018

• Behar E, Bagnulo R, Coffin PO. Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review. Prev Med. 2018 Sep;114:79-87. doi: 10.1016/j.ypmed.2018.06.005. PMID: 29908763.

​

• Do V, Behar E, Turner C, Geier M, Coffin P. Acceptability of Naloxone Dispensing Among Pharmacists. J Pharm Pract. 2018 Sep 4:897190018798465. doi: 10.1177/0897190018798465. PMID: 30180774.​​

​

• Rowe C, Wheeler E, Vittinghoff E, Santos GM, Behar E, Coffin PO. Quantity fluctuations of illicitly used opioids and overdose risk. Int J Drug Policy. 2018 May 25;58:64-70. doi: 10.1016/j.drugpo.2018.05.004. PMID: 29807248​

​

• Rowe C, Wheeler E, Jones TS, Yeh C, Coffin PO. Community-based response to fentanyl overdose outbreak, San Francisco, 2015. Journal of Urban Health. 2018 May 3. doi: 10.1007/s11524-018-0250-x. PMID: 29725887.​

​

• Hurstak E, Rowe C, Turner C, Behar E, Cabugao R, Lemos N, Coffin PO. Using medical examiner case narratives to improve opioid overdose surveillance. International Journal of Drug Policy. 2018 Jan 17;54:35-42. doi: 10.1016/j.drugpo.2017.12.017. PMID: 29353022.

​

2017

• Coffin PO, Santos G-M, Matheson T, Behar E, Rowe C, Rubin T, Silvis J, Vittinghoff E. Behavioral intervention to reduce opioid overdose among high-risk persons with opioid use disorder: a pilot randomized controlled trial. Plos One. October 2017;12(10):e0183354. doi: 10.1371/journal.pone.0183354. PMID: 29049282.

​

• Rowe C, Santos GM, Raymond HF, Coffin PO. Social mixing and correlates of injection frequency among opioid use partnerships. Int J Drug Policy. 2017 Mar;41:80-88. doi: 10.1016/j.drugpo.2016.11.016. PMID: 28113118

​

• Behar E, Rowe C, Santos G-M, Santos N, Coffin PO. Academic detailing pilot for naloxone prescribing among primary care providers in San Francisco. Family Medicine. 2017 Feb;49(2):122-126. PMID: 28218937

​

2016

• Wen L, Goodwin K, Coffin PO, Behar E. Promoting Overdose Prevention through Policy, Education and Outreach. NACCHO Exchange: Promoting Effective Local Public Health Practice. 2016;16(1):13-17.​​​

​

• Behar E, Rowe C, Santos G-M, Coffa D, Turner C, Santos N, Coffin PO. Acceptability of naloxone co-prescription among primary care providers treating patients on long-term opioid therapy for pain. Journal of General Internal Medicine. 2016 Nov 4. doi: 10.1007/s11606-016-3911-z. PMID 27815762.​​​

​

• Rowe C, Vittinghoff E, Santos G-M, Behar E, Turner C, Coffin PO. Performance measures of diagnostic codes for detecting opioid overdose in the emergency department. Academic Emergency Medicine. 2016 Oct 20. doi: 10.1111/acem.13121. PMID: 27763703.

​

• Behar E, Rowe C, Santos G-M, Murphy S, Coffin PO. Primary Care Patient Experience with Naloxone Prescription. Annals of Family Medicine. 2016 Sep;14(5):431-6. doi: 10.1370/afm.1972. PMID: 27621159.

​

• Coffin PO, Behar E, Rowe C, Santos GM, Coffa D, Bald M, Vittinghoff E. Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain. Ann Intern Med. 2016 Aug 16;165(4):245-52. doi: 10.7326/M15-2771. PMID: 27366987.

​

• Rowe C, Santos GM, Vittinghoff E, Wheeler E, Davidson P, Coffin PO. Neighborhood-level and spatial characteristics associated with lay naloxone reversal events and opioid overdose deaths. Journal of Urban Health. 2016 Feb;93(1):117-130. Doi: 10.1007/s11524-015-0023-8. PMID 26800987.​​

​

2015

• Rowe C, Santos GM, Behar E, Coffin PO. Correlates of overdose risk perception among illicit opioid users. Drug and Alcohol Dependence. 2015 Dec 30. pii: S0376-8716(15)01833-5. doi: 10.1016/j.drugalcdep.2015.12.018. PMID: 26754425.

​

• Rowe C, Santos M, Wheeler E, Vittinghoff E, Davidson P, Coffin PO. Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program. Addiction. 2015 Aug;110(8):1301-10. DOI:10.1111/add.12961. PMID: 25917125.​​

​

• Visconti A, Santos G-M, Lemos N, Burke C, Coffin PO. Opioid Overdose Deaths in the City and County of San Francisco: Prevalence, Distribution, and Disparities. Journal of Urban Health. 2015 Aug;92(4):758-72. doi: 10.1007/s11524-015-9967-y. PMID 26077643

​

• Coffin PO. Naloxone for Opioid Safety. San Francisco Medicine: Journal of the San Francisco Medical Society. July/August 2015. 88(6):12-13.​​

​

• ​Behar E, Santos GM, Wheeler E, Rowe C, Coffin PO. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug and Alcohol Dependence. 2015 Mar 1;148:209-12. doi: 10.1016/j.drugalcdep.2014.12.009. PMID: 25595053.

​

• Coffin PO. Prevention of lethal opioid overdose in the community. UpToDate. 2015.​​​

​

2013-2014

• Coffin P, Banta-Green C. The dueling obligations of opioid stewardship. Annals of Internal Medicine. 2014; 160(3):207-208. doi:10.7326/M13-2781. PMID: 24322334.

​

• Coffin PO, Sullivan SD. Cost-effectiveness of naloxone distribution to heroin users for lay overdose reversal in Russian cities. Journal of Medical Economics. 2013; 16(8):1051-1060. Doi: 10.3111/13696998.2013.811080. PMID: 23730942​​​

2019

• Freeborn K, Portillo C, Boyer CB, Santos GM. Misclassification of sexual health risks in a self-identified low risk cohort of men who have sex with men (MSM) enrolled in a community based PrEP program. AIDS Care. 2019 May 25; 1-8. doi: 10.1080/09540121.2019.1620167. PMID: 31129982.

​

• Prescott MR, Hern J, Petersen M, Santos GM. Does HIV Pre-Exposure Prophylaxis Modify the Effect of Partnership Characteristics on Condom Use? A Cross-Sectional Study of Sexual Partnerships Among Men Who Have Sex with Men in San Francisco, California. AIDS Patient Care STDS. 2019 Apr; 33(4):167-174. doi: 10.1089/apc.2018.0179. PMID: 30932698.​

​

2017

• Brown R, Turner C, Hern J, Santos GM. Partner-level substance use associated with increased sexual risk behaviors among men who have sex with men in San Francisco, CA. Drug and Alcohol Dependence. 2017 Jul 1;176:176-180. DOI: http://dx.doi.org/10.1016/j.drugalcdep.2017.02.016. PMID: 28549302

​

• Turner CM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Batki S, Santos GM. Race/ethnicity, education, and age are associated with engagement in ecological momentary assessment text messaging among substance-using MSM in San Francisco. Journal of Substance Abuse Treatment. 2017 Apr;75:43-48. doi: 10.1016/j.jsat.2017.01.007. PMID 28237053.​​

​

2016

• Ayala G, Santos GM. Will the global HIV response fail gay and bisexual men and other men who have sex with men? J Int AIDS Soc. 2016 Nov 21;19(1):21098. doi: 10.7448/IAS.19.1.21098. PMID: 27876454.

​

• Rowe C, Hern J, DeMartini A, Jennings D, Sommers M, Walker J, Santos GM. Concordance of Text Message Ecological Momentary Assessment and Retrospective Survey Data Among Substance-Using Men Who Have Sex With Men: A Secondary Analysis of a Randomized Controlled Trial. JMIR Mhealth Uhealth. 2016 May 26;4(2):e44. doi: 10.2196/mhealth.5368. PMID: 27230545.

​

• Santos GM, Coffin P, Santos D, Huffaker S, Matheson T, Euren J, DeMartini A, Rowe C, Hahn JA, Vlahov D, Vittinghoff E, Batki SL. Feasibility, Acceptability, and Tolerability of Targeted Naltrexone for Nondependent Methamphetamine-Using and Binge-Drinking Men Who Have Sex with Men. J Acquir Immune Defic Syndr. 2016 May 1;72(1):21-30. doi: 10.1097/QAI.0000000000000922. PMID: 26674372.

​

• Rowe C, Matheson T, Das M, DeMicco E, Herbst JH, Coffin PO, Santos G-M. Correlates of recent HIV testing among substance-using men who have sex with men. International Journal of STD & AIDS. 2016. Mar 21. doi: 10.1177/0956462416640964. PMID: 27000299.​​

​

2014

• Coffin PO, Santos GM, Colfax G, Das M, Matheson T, DeMicco E, Dilley J, Vittinghoff E, Raiford JL, Carry M, Herbst JH. Adapted personalized cognitive counseling for episodic substance-using men who have sex with men: a randomized controlled trial. AIDS Behav. 2014 Jul;18(7):1390-400. doi: 10.1007/s10461-014-0712-4. PMID: 24510401.

​

• Santos GM, Coffin PO, Vittinghoff E, Das M, DeMicco E, Matheson T, Raiford J, Dilley J, Colfax G, Herbst J. Substance Use and Drinking Outcomes in Personalized Cognitive Counseling Trial for Episodic Substance-using Men who have sex with Men. Drug and Alcohol Dependence. 2014 Feb 24. pii: S0376-8716(14)00070-2. doi: 10.1016/j.drugalcdep.2014.02.015. PMID: 24641808.​​​

​

2011-2013

• Santos GM, Coffin PO, Das M, Matheson T, DeMicco E, Raiford J, Vittinghoff E, Dilley J, Colfax G, Herbst J. Dose-response associations between number and frequency of substance use and high-risk sexual behaviors among HIV-negative substance-using men who have sex with men (SUMSM) in San Francisco. Journal of Acquired Immunodeficiency Syndromes. 2013; 63(4):540-544. PMID 23572012​​

​

• Santos GM, Das M, Colfax GN. Interventions for non-injection substance use among US men who have sex with men: what is needed. AIDS Behav. 2011 Apr; 15 Suppl 1:S51-6. PMID: 21404011.

2021 год

• Аппа А., Родда Л.Н., Коули С., Зевин Б., Коффин П.О., Ганди М., Имберт Э. Смертность от передозировки наркотиков до и после приказов о предоставлении убежища на месте во время пандемии COVID-19 в Сан-Франциско . Открытие JAMA Netw. 2021 г., 3 мая;4(5):e2110452. doi: 10.1001/jamanetworkopen.2021.10452. PMID: 33978726.

2020 год

• Бамбергер Дж., Мехтани Н., Ристау Дж., Зевин Б., Коффин П. Практика и инновации снижения вреда в ответ на пандемию COVID-19 в Сан-Франциско . Коллаборативный институт правосудия. 8 декабря 2020 г. https://tjcinstitute.com/research/sf-harm-reduction/

• Аппа А., Роу С., Хессол Н.А., Коффин П. Помимо передозировки: смертность, связанная с наркотиками, среди людей с ВИЧ и без него в Сан-Франциско, 2007–2018 гг . Открыть форум Infect Dis. 18 ноября 2020 г.;7(12):ofaa565. doi: 10.1093/ofid/ofaa565. eCollection 2020, декабрь PMID: 33409331

• Гроб П.О., Роу К. Национальная система раннего предупреждения о наркотиках (NDEWS), структура и тенденции употребления наркотиков на сайте дозорного сообщества Сан-Франциско, 2020 г. Колледж-Парк, Мэриленд: Координационный центр NDEWS. Август 2020.

• Коффин П.О., Роу С., Гербино Н. Тенденции употребления психоактивных веществ в Сан-Франциско в 2019 году . Департамент общественного здравоохранения Сан-Франциско, август 2020 г. Сан-Франциско, Калифорния.

​

2019 год

• Коффин П.О., Роу С., Биркамп А. Тенденции употребления психоактивных веществ в Сан-Франциско в 2018 году . Департамент общественного здравоохранения Сан-Франциско, декабрь 2019 г. Сан-Франциско, Калифорния.

• Коффин П.О., Роу К. Национальная система раннего предупреждения о наркотиках (NDEWS), Паттерн и тенденции употребления наркотиков на сайте дозорного сообщества Сан-Франциско, 2019 . Колледж-Парк, Мэриленд: Координационный центр NDEWS. Ноябрь 2019.

​

2018 год

• Коффин П.О., Роу К. Национальная система раннего предупреждения о наркотиках (NDEWS), Паттерн и тенденции употребления наркотиков на сайте дозорного сообщества Сан-Франциско, 2018 г. Колледж-Парк, Мэриленд: Координационный центр NDEWS. Ноябрь 2018.

• Тернер С., Чандракумар Д., Роу С., Сантос Г.М., Райли Э.Д., Гроб П.О. Сравнение перекрестных причин смертности от стимуляторов и опиоидов в Сан-Франциско, 2005–2015 гг . Наркотическая и алкогольная зависимость. 21 февраля 2018 г. doi: 10.1016/j.drugalcdep.2017.12.030. PMID: 29486419.​

​

2017 год

• Коффин П.О., Роу К. Национальная система раннего предупреждения о наркотиках (NDEWS), Образцы и тенденции употребления наркотиков на сайте дозорного сообщества Сан-Франциско, 2017 г. Колледж-Парк, Мэриленд: Координационный центр NDEWS. Ноябрь 2017.

2025​

• Black F, McMahan VM, Chang G, Rodda LN, Coffin PO. Thematic analysis of medical examiner narratives to understand the socio-spatial context, recency of drug use, and likely mechanism of stimulant toxicity deaths. Drug and Alcohol Dependence. 2025 Apr.doi: 10.1016/112700.

​

• Antolin Muniz M, McMahan VM, Luna Marti X, Brennan S, Tavasieff S, Rodda LN, Knoll J, Coffin PO. Identification of Behavioral, Clinical, and Psychological Antecedents of Acute Stimulant Poisoning: Development and Implementation of a Mixed Methods Psychological Autopsy Study. JMIR Form Res. 2025 Jan 13:9:e64873. doi: 10.2196/64873. PMID: 39815401.

2021​

• Beliveau CM, McMahan VM, Arenander J, Angst MS, Kushel M, Torres A, Santos GM, Coffin PO. Stimulant use for self-management of pain among safety-net patients with chronic non-cancer pain. Subst Abus. 2021 Apr 2:1-8. doi: 10.1080/08897077.2021.1903654. PMID: 33798030.

​

• Rowe CL, Santos GM, Kornbluh W, Bhardwaj S, Faul M, Coffin PO. Using ICD-10-CM codes to detect illicit substance use: A comparison with retrospective self-report. Drug Alcohol Depend. 2021 Apr 1;221:108537. doi: 10.1016/j.drugalcdep.2021.108537. PMID: 33621806.

​

• Bongiovanni, T. Hernandez, S. Ledesma, Y. Menza, R. Wick, E. Steinman, M. Mackersie, R. Stein, D. Coffin, P. Surviving traumatic injury to die of acute drug poisoning: do trauma centers need to be a path for intervention? Surgery. In press. 

​

• Santos G-M, Ikeda J, Coffin P, Walker JE, Matheson T, McLaughlin M, et al. (2021) Pilot study of extended-release lorcaserin for cocaine use disorder among men who have sex with men: A double-blind, placebo-controlled randomized trial. PLoS ONE 16(7): e0254724. https://doi.org/ 10.1371/journal.pone.0254724

​

2020

• Navadeh S, Mirzazadeh A, McFarland W, Coffin P, Chehrazi M, Mohammad K, Nazemipour M, Mansournia MA, McCandless LC, Page K. Unsafe Injection Is Associated with Higher HIV Testing after Bayesian Adjustment for Unmeasured Confounding. Arch Iran Med. 2020 Dec 1;23(12):848-855. doi: 10.34172/aim.2020.113. PMID: 33356343.

​

• Riley ED, Vittinghoff E, Wu AHB, Coffin PO, Hsue PY, Kaz DS, Wade A, Braun C and Lynch KL. Impact of Polysubstance Use on High-Sensitivity Cardiac Troponin I over Time in Homeless and Unstably Housed Women. Drug and Alcohol Dependence. 2020 Aug 30;217:108252. doi: 10.1016/j.drugalcdep.2020.108252. PMID: 32919207 

​

2019

• Morris M, Page K, Mirzazadeh A, Coffin P, Briceno A, Evans J, Hahn J. Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: low number treated. Drug and Alcohol Dependence. 2019. 198:133-135. doi: 10.1016/j.drugalcdep.2019.02.008. PMID: 30921649. 

​

• Coffin PO, Santos G-M, Behar E, Hern J, Walker JE, Matheson T, Kinnard E, Silvis J, Vittinghoff E, Fox R, Page K. Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs. Plos One. Jun 3;14(6):e0217471. doi: 10.1371/journal.pone.0217471. eCollection 2019. PMID: 31158245.

​

​​​2018

• Ayala G, Santos GM, Arreola S, Garner A, Makofane K, Howell S. Blue-Ribbon Boys: factors associated with PrEP use, ART use and undetectable viral load among gay app users across six regions of the world. J Int AIDS Soc. 2018 Jul; 21 Suppl 5:e25130. doi: 10.1002/jia2.25130. PMID: 30033536.​

​

2014

• Dacarett-Galeano DJ, Santos GM, Santos D, Das M, Coffin PO. Spatial and neighborhood-level correlates of retention in pharmacologic efficacy trials. Drug and Alcohol Dependence. 2014;140:e42. doi:10.1016/j.drugalcdep.2014.02.137.​

​

• Coffin PO, Reynolds A. Ending hepatitis C in the United States: the role of screening. Hepatic Medicine: Evidence and Research. Invited manuscript; 2014 Jul 3;6:79-87. DOI: 10.2147/HMER.S40940. PMID:25114602.​